2015 Fiscal Year Final Research Report
Development of adjuvant therapy targeted to lipid-derived reactive aldehydes-metabolizing enzymes
| Project/Area Number |
25460068
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Gifu Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | シスプラチン / 肺がん / 抗がん剤耐性化 / アルドケト還元酵素 |
|---|
| Outline of Final Research Achievements |
In this study, I found up-regulation of aldo-keto reductase (AKR) 1B10, an enzyme that detoxifies lipid-derived reactive aldehydes, by development of cisplatin (CDDP)-resistance in lung cancer cells. In addition, the treatment with CDDP enhanced the nitric oxide production, which may participate in mechanism of the AKR1B10 induction. Furthermore, pretreating with AKR1B10 inhibitor overcame the CDDP resistance, suggesting the availability of the inhibitor in adjuvant therapy for CDDP treatment of lung cancer.
|
| Free Research Field |
生物系薬学
|
